Skip Navigation

Cardiovascular Research 2004 61(2):352-359; doi:10.1016/j.cardiores.2003.11.017
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Stegbauer, J.
Right arrow Articles by Rump, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stegbauer, J.
Right arrow Articles by Rump, L. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Angiotensin-(1–7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats

Johannes Stegbauer, Vitus Oberhauser, Oliver Vonend and Lars Christian Rump*

Department of Internal Medicine I, Marienhospital Herne, Ruhr-University Bochum, Hölkeskampring 40, D-44625 Herne, Germany

* Corresponding author. Tel.: +49-2323-499-1671; fax: +49-2323-499-302. christian.rump{at}ruhr-uni-bochum.de

Objective: Angiotensin (Ang)-(1–7) generated from Ang I and II is reported to act as an endogenous angiotensin-converting enzyme (ACE) inhibitor and angiotensin type 1 (AT1)-receptor antagonist in vitro and in vivo. Ang-(1–7) has been suggested to play an important role in hypertension. Methods and results: Therefore, we tested whether Ang-(1–7) differentially modulates vascular resistance and neurotransmission in isolated kidneys of spontaneously hypertensive rats stroke prone (SHR-SP) and Wistar–Kyoto rats (WKY). Ang-(1–7) was administered in three concentrations (0.1, 1 and 10 µmol/l) to prevent Ang I- and Ang II-induced pressor responses and facilitation of noradrenaline release. There were indeed concentration-dependent strain differences. Ang-(1–7) prevented Ang I- and Ang II-mediated changes in vascular resistance more potently in SHR-SP than in WKY by inhibiting ACE and by blocking AT1-receptors. Ang-(1–7) by itself had no influence on renal vascular tone in both strains. Ang-(1–7) inhibited Ang I-mediated facilitation of noradrenaline release more potently than Ang II-mediated facilitation of noradrenaline release. Ang-(1–7) by itself enhanced noradrenaline release from SHR-SP, but not from WKY kidneys. Conclusion: Ang-(1–7) had a greater impact on Ang I and Ang II modulation of renal vascular resistance in SHR-SP than in normotensive rats. Furthermore, Ang-(1–7) by itself has facilitatory presynaptic effects on noradrenaline release but no postsynaptic effects on renal vascular resistance in SHR-SP. Since plasma levels of Ang-(1–7) accumulate during ACE-inhibitor or AT1-receptor antagonist therapy, Ang-(1–7) could contribute to antihypertensive effects of these agents.

KEYWORDS Angiotensin-(1–7); Renin-angiotensin-system; Noradrenaline release; Vascular resistance; Experimental hypertension

Time for primary review 21 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.